Mostrar el registro sencillo del ítem
dc.contributor.author | Guzman-Fulgencio, Maria | |
dc.contributor.author | Berenguer, J | |
dc.contributor.author | Pineda-Tenor, Daniel | |
dc.contributor.author | Jimenez-Sousa, Maria Angeles | |
dc.contributor.author | Garcia-Alvarez, Monica | |
dc.contributor.author | Aldámiz-Echevarria, T | |
dc.contributor.author | Carrero, A | |
dc.contributor.author | Diez, C | |
dc.contributor.author | Tejerina, F | |
dc.contributor.author | Vázquez-Morón, Sonia | |
dc.contributor.author | Briz, Veronica | |
dc.contributor.author | Resino, Salvador | |
dc.date.accessioned | 2024-05-21T13:02:22Z | |
dc.date.available | 2024-05-21T13:02:22Z | |
dc.date.issued | 2015-02 | |
dc.identifier.citation | Eur J Clin Microbiol Infect Dis. 2015 Feb;34(2):385-93. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/19510 | |
dc.description.abstract | Interleukin-7 (IL-7) is a critical factor in maintaining or inducing effective antiviral CD4+ and CD8+ T-cell responses. The aim of this study was to examine the association of interleukin-7 receptor-α (IL7RA) polymorphisms with a sustained virologic response (SVR) after hepatitis C virus (HCV) therapy with pegylated interferon-alpha plus ribavirin (pegIFNα/ribavirin) in 177 human immunodeficiency virus (HIV)/HCV-coinfected patients. We performed a retrospective study in 177 naïve patients who started HCV treatment. The IL7RA rs6897932, rs987106, and rs3194051 polymorphisms were genotyped by the GoldenGate® assay. An SVR was defined as undetectable HCV viral load through 24 weeks after the end of HCV treatment. The highest SVR rate was found in patients with the rs6897932 CC (p = 0.029) and rs3194051 GG (p = 0.002) genotypes, and HCV genotypes 2/3 (GT2/3) infected patients with the rs987106 AA genotype (p = 0.048). Additionally, carriers of the rs3194051 GG genotype had a higher likelihood of achieving an SVR [adjusted odds ratio (aOR) = 5.32; 95 % confidence interval (CI) = 1.07-26.94; p = 0.040] than patients with the rs3194051 AA/AG genotype, while rs6897932 CC (aOR = 0.63; p = 0.205) and rs987106 AA (aOR = 0.60; p = 0.213) were not significant. Moreover, three major haplotypes were found: 46.6 % for CTA, 32.4 % for CAG, and 20.7 % for TAA haplotypes. Patients infected with GT2/3 and carriers of the CTA haplotype had lower odds of achieving an SVR (aOR = 0.08; p = 0.004) and the CAG haplotype (favorable alleles) had higher odds of achieving an SVR than other haplotypes (aOR = 21.96; p < 0.001). IL7RA polymorphisms seem to play a significant role in the virological response to pegIFNα/ribavirin therapy in HIV/HCV-coinfected patients, in particular among patients infected with HCV GT2/3. | es_ES |
dc.description.sponsorship | This work has been supported by grants given by Fondo de Investigación de Sanidad en España (FIS) (Spanish Health Funds for Research) (grant numbers PI08/0738, PI11/00245, PI08/0928, and PI11/01556) and Fundación para la Investigación y la Prevención del Sida en España (FIPSE) (grant number 361020/10). This work has been (partially) funded by the RD12/0017/0024 and RD12/0017/0004 projects as part of the Plan Nacional R+D+ I and cofinanced by ISCIII Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS; Refs INT10/009 and INT12/154). Moreover, DP-T, MG-F, MAJ-S and MG-A are supported by Instituto de Salud Carlos III (grant numbers CM12/00043, RD12/0017/0024, CD13/00012 and CD12/00442 respectively). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Springer | es_ES |
dc.type.hasVersion | AM | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject.mesh | Polymorphism, Genetic | es_ES |
dc.subject.mesh | Adult | es_ES |
dc.subject.mesh | Alleles | es_ES |
dc.subject.mesh | Antiviral Agents | es_ES |
dc.subject.mesh | Coinfection | es_ES |
dc.subject.mesh | Drug Therapy, Combination | es_ES |
dc.subject.mesh | Female | es_ES |
dc.subject.mesh | Genotype | es_ES |
dc.subject.mesh | HIV Infections | es_ES |
dc.subject.mesh | Haplotypes | es_ES |
dc.subject.mesh | Hepacivirus | es_ES |
dc.subject.mesh | Hepatitis C | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Interferon alpha-2 | es_ES |
dc.subject.mesh | Interferon-alpha | es_ES |
dc.subject.mesh | Interleukin-7 | es_ES |
dc.subject.mesh | Male | es_ES |
dc.subject.mesh | Odds Ratio | es_ES |
dc.subject.mesh | Polyethylene Glycols | es_ES |
dc.subject.mesh | Recombinant Proteins | es_ES |
dc.subject.mesh | Retrospective Studies | es_ES |
dc.subject.mesh | Ribavirin | es_ES |
dc.title | Association between IL7RA polymorphisms and the successful therapy against HCV in HIV/HCV-coinfected patients | es_ES |
dc.type | research article | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 25236396 | es_ES |
dc.format.volume | 34 | es_ES |
dc.format.number | 2 | es_ES |
dc.format.page | 385-393 | es_ES |
dc.identifier.doi | 10.1007/s10096-014-2245-1 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Fundación para la Investigación y la Prevención del Sida en España | es_ES |
dc.contributor.funder | Plan Nacional de I+D+i (España) | es_ES |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1435-4373 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1007/s10096-014-2245-1 | es_ES |
dc.identifier.journal | European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PI08/0738 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MICINN//PI11%2F00245/ES/Erradicación del VHC en pacientes coinfectados por VIH%2FVHC: efectos sobre la inflamación, el daño endotelial, la activación inmune y la aterosclerosis preclínica/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PI08/0928 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MICINN//PI11%2F01556/ES/Erradicación del VHC en pacientes coinfectados por VIH%2FVHC: efectos sobre la inflamación, el daño endotelial, la activación inmune y la aterosclerosis preclínica/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/INT10/009 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/INT12/154 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//CM12%2F00043/ES/CM12%2F00043/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//RD12%2F0017%2F0024/ES/SIDA/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/CD13/00012 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//CD12%2F00442/ES/CD12%2F00442/ | es_ES |